At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy (device)
- How long the study runs
- Study runs about 10 months (dates as stated)
- About the drug or intervention
- CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy — device: 1.
- Patient visit burden
- Not specified by the sponsor
In plain English
This study, run by University College London, is called the Early Diagnosis Real-Time Healthcare System for Cancer Trial. It looks at colonoscopy procedures in people who have or may have growths in the bowel called polyps. Details of what the trial is testing are not fully stated — ask the trial team.
Who can take part
- Due to have a colonoscopy (a camera test of the bowel) for screening, surveillance (checking) or symptoms, with a doctor taking part in this trial
- Aged 18 or over, male or female
- Able to understand and sign a consent form
Who may not be able to
- Having an emergency or inpatient colonoscopy
- Having inflammatory bowel disease (IBD)
- Currently having colorectal cancer (bowel cancer)
- Unable to safely have a biopsy (tissue sample) or polyp removal — for example, not having stopped blood-thinning medicines as advised, or having a bleeding or clotting disorder (such as haemophilia, Von Willebrand's disease, low platelets, or cirrhosis with clotting problems)
- Taking part in another research study involving a medicine or treatment that could raise bleeding risk
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 420
- Started
- 2024-07-18
- Last checked
- 2024-12
Plain English Summary
What is this study?
- • Testing a new treatment for polyps
- • Clinical study - 420 participants
- • The purpose of the study is to assess whether the AI characterisation system of the CADDIE device improves the endoscopists accuracy in the optical diagnosis of diminutive colorectal polyps in the bowel during colonoscopy
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with polyps
Where?
- • London - University College London Hospitals NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of the study is to assess whether the AI characterisation system of the CADDIE device improves the endoscopists accuracy in the optical diagnosis of diminutive colorectal polyps in the bowel during colonoscopy. Participants will either have a colonoscopy with the assistance of the CADDIE device characterisation AI system ("intervention group") or have a colonoscopy in line with routine clinical practice i.e., without the CADDIE device characterisation AI system ("control group"). The randomisation method of this trial will allocate enrolled participants to the "intervention" group and to the "control" group by a technique similar to flipping a coin.
More detail
The CADDIE system comprises a computer attached to the output of the endoscopy stack and a screen which shows the normal video output of the colon in real-time. Using artificial intelligence (AI) software, it highlights the characteristics of a polyp to help the endoscopist in their optical diagnosis of the polyp histology. Pressing on a foot pedal, which is connected to the computer, presents the information from the AI software to the user as an overlay on the endoscopy screen in text format. The CADDIE device is capable of recording the video output of the colon in real-time irrespective of whether the CADDIE's AI system is active. In the endoscopist recruitment phase, we will identify endoscopists expertise and experience in colonoscopy. In the study phase of the trial, the endoscopist will be kept the same for the CADDIE and control arm. At the beginning of each procedure, participant information will be entered into an electronic system (Redcap) which will generate a random allocation into one of two arms. The CADDIE arm involves a colonoscopy assisted by the CADDIE AI system (i.e., AI software). The control arm is a colonoscopy without the CADDIE's polyp characterisation AI system (i.e., standard practice). Each endoscopist will have the CADDIE device present during all endoscopy lists and will record all procedures in both CADDIE and control arms. The CADDIE's polyp characterisation system (i.e., AI software) will only be active in the CADDIE arm. The recordings in the control arms will allow an extra post-hoc assessment of how CADDIE might have performed compared to the actual assessment by the endoscopist. In both arms of the trial, for each polyp the endoscopist detects, they will: 1. Measure the polyp size and capture images of the polyp: Polyps are to be measured using an instrument of known size. For polyps measured to be \<10mm, the endoscopist will capture a still image of the polyp in both white light and Narrow Band Imaging (NBI) or equivalent imaging modality. 2. Optically diagnose the polyp: The endoscopist will optically diagnosis polyps \<10mm, stating whether the diagnosis is made with high or low confidence. 3. Resect diminutive polyps: Management of rectosigmoid hyperplastic polyps will be standardised. Rectosigmoid polyps that are optically diagnosed as hyperplastic by the endoscopist will be resected/biopsied. If multiple rectal hyperplastic polyps are optically diagnosed by the endoscopist, a maximum of 5 will be resected/biopsied for histopathology. 4. Label the polyp with unique ID: Each polyp resected (regardless of size) must be labelled according to instructions of the Specimen Handling SOP. Each unique polyp ID will be logged in chronological order on a per colonoscopy basis and sent for histopathology. Histopathology will be referenced as the ground truth for polyp diagnosis and characterisation. 5. Complete documentation as per standard of care: Documentation will be made in the endoscopy report of polyp site, size, morphology, segmental Boston Bowel Preparation Score (BBPS). A photograph will also be taken of the caecum and stored in the endoscopy report. 6. Complete the optical diagnosis case report form (CRF): Populate the optical diagnosis CRF at the end of the procedure with the polyp ID of each polyp sample (regardless of size), their optical diagnosis of each polyp \<10mm in size and whether their optical diagnosis was made with high or low confidence. In the CADDIE arm, the endoscopist presses the foot pedal once they have frozen an image of the polyp in the endoscopy screen in narrow band imaging (NBI) mode. This will output the CADDIE's characterisation of the polyp. Using this information and the endoscopist's own assessment, the endoscopist will log an optical diagnosis of the polyp and the confidence of their diagnosis (high or low). In the control arm, the endoscopist optically diagnoses the polyps without CADDIE's polyp characterisation function. The optical diagnosis will be assessed against the polyp histopathology which will be referred as the ground truth. Post-hoc analysis of the recorded footage will allow for comparison with the CADDIE generated polyp characterisation. Safety of the device will be assessed through monitoring of adverse events. Acceptability will be assessed through a qualitative questionnaire for the endoscopist, endoscopy nurse and participant in addition to measuring endoscopy markers such as caecal intubation time, procedural time, withdrawal time.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Participants scheduled to undergo a screening, surveillance or causing symptoms colonoscopy with an endoscopist...
- ✓Male and female participants aged 18 years or older at the time of agreement to take part.
- ✓Participants able to comprehend, sign and date the written agreement to take part document to participate in the study.
Who cannot take part
- ✗Emergency and/or inpatient colonoscopies
- ✗Participants with inflammatory bowel disease (IBD)
- ✗Participants with current Colorectal Cancer (CRC)
- ✗Participants with a safety concern for biopsy or polypectomy. These include:
- ✗Participants who have not withheld medications pre-disposing to bleeding at time of colonoscopy as per local site...
See the full criteria
Where Is This Study? (1 UK site)
University College London Hospitals NHS Foundation Trust
London NW1 2PG, United Kingdom
Rajinder Sidhu - Associate Director, Research Governance and Operations
uclh.jro-communications@nhs.net020 3447 9825How to Get in Touch
Sharon Cheung, MSc
Sponsor contactCONTACT
Rawen Kader, MBBS MRCP
Sponsor contactCONTACT
